How much funding has Canal Biosciences raised?

Canal Biosciences has disclosed $2.3M raised across 1 round.

Where is Canal Biosciences headquartered?

Canal Biosciences is headquartered in Lowell, US.

Canal Biosciences

Lowell, US · Founded 2024 · Delaware corporation

Canal Biosciences develops DNA library preparation technology for next-generation sequencing, centered on its TrueLink platform and DISTAL-seq products that attach sequencing adaptors to native DNA termini without end repair to preserve template integrity. Its methods target high-precision NGS applications such as liquid biopsy, methylation sequencing, and minimal residual disease detection in cancer.

BiotechDeep TechMedical Devices

Founders & leadership

Jack PercoskieinExecutive

Christopher BenoitNamed on SEC filing

Yu ZhenginNamed on SEC filing

Reported raises · per SEC filings

Form D private placements

$2.3M disclosed across 1 round · 2026

▶$2.3MraisedApr 2026 · 18 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Christopher BenoitExecutive Officer, Director
Jack PercoskieExecutive Officer
Yu ZhengExecutive Officer, Director

Offering amount: $3.2M
Amount sold: $2.3M
First sale: Mar 2026
Incorporated: Corporation, Delaware, 2024
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap

Portal Innovations4 shared keywordsPortal Innovations is a venture development platform for science-driven and life science entrepreneurs, providing seed capital, equipped lab space, and connections to investors and partners. It focuses on supporting biomedical innovation and building companies in entrepreneurs' local ecosystems.

Companies competing with Canal Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Canal Biosciences do?: Canal Biosciences develops DNA library preparation technology for next-generation sequencing, centered on its TrueLink platform and DISTAL-seq products that attach sequencing adaptors to native DNA termini without end repair to preserve template integrity. Its methods target high-precision NGS applications such as liquid biopsy, methylation sequencing, and minimal residual disease detection in cancer.
How much funding has Canal Biosciences raised?: Canal Biosciences has disclosed $2.3M raised across 1 round.
Where is Canal Biosciences headquartered?: Canal Biosciences is headquartered in Lowell, US.